Reclassifying HFmrEF as a stable phenotype aims to reduce therapeutic inertia and GDMT underuse driven by heterogeneous ...

The heart failure (HF) treatment landscape continues to evolve rapidly in 2026, with emerging evidence pointing toward a ...

Cardiosense, a healthcare technology company focused on heart failure care, today announced that the U.S. Food & Drug Administration (FDA) has granted De Novo classification for its PCWP Analysis ...

Functional assessment and classification in heart failure encompass a spectrum of tools and frameworks designed to quantify a patient’s symptoms, exercise capacity and underlying cardiac performance.

A new gene therapy can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the amount of blood the heart can pump and dramatically improves ...

BNP levels are sensitive to such other biological factors as age, gender, sex, weight, and renal function. BNP levels may be elevated in cases of acute MI, pulmonary embolism, and chronic obstructive ...

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally, sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...

Heart failure is when the heart does not pump enough blood around the body. Biventricular heart failure is when chambers on both sides of the heart, known as ventricles, are affected. Doctors classify ...